Surveillance of adverse effects following vaccination and safety of immunization programs;Vigiláncia de eventos adversos ṕs-vacinaçáo e segurança de programas de imunizaçáo

Revista de Saude Publica

Volumn 45, Issue 1, 2011, Pages 173-184

  Waldman, Eliseu Alves ^a   Luhm, Karin Regina ^b   Monteiro, Sandra Aparecida Moreira Gomes ^c   de Freitas, Fabiana Ramos Martin ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

Author keywords

Adverse effects; Clinical Trials; Immunization Programs; Phase IV as Topic; Postmarketing; Product Surveillance; Review; Vaccines

Indexed keywords

ARTICLE; DRUG SURVEILLANCE PROGRAM; HUMAN; METHODOLOGY; POSTMARKETING SURVEILLANCE; PREVENTIVE HEALTH SERVICE; STANDARD; VACCINATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; IMMUNIZATION PROGRAMS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 78650582422     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102011000100020     Document Type: Article

References (114)

1. Ali M, Cahn GD, Clemens JD, Park JK, von Seidlein L, Minh TT, Thiem DV, et al. The use of a computerized database to monitor vaccine safety in Viet Nam. Bull World Health Organ. 2005;83(8):604-10. DOI:10.1590/S0042-96862005000800014.
2. Anderson MM, Rone T. Side-effects with Japanese encephalitis vaccine. Lancet. 1991;337(8748):1044. DOI:10.1016/0140-6736(91)92707-9.
3. André FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine. 2003;21(7-8):593-5. DOI:10.1016/S0264-410X(02)00702-8.
4. Arruda WO, Kondageski C. Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Paraná, Brazil, 1998. Rev Inst Med Trop S Paulo. 2001;43(5):301-2. DOI:10.1590/S0036-46652001000500012.
5. Bambini S, Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov Today. 2009;14(5-6):252-60. DOI:10.1016/j.drudis.2008.12.007.
6. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et al. The risk of seizures after receipt of whole -cell pertussis or measles, mumps and rubella vaccine. N Engl J Med. 2001;345(9):656-61. DOI:10.1056/NEJMoa003077.
7. Begg N, Miller E. Role of epidemiology in vaccine policy. Vaccine. 1990;8(3):180-9. DOI:10.1016/0264-410X(90)90042-K.
8. Bonanni P, Bergamini M. Factors influencing vaccine uptake in Italy. Vaccine. 2001;20 (Suppl 1):S8-12. DOI:10.1016/S0264-410X(01)00284-5.
9. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21(3-4):298-302. DOI:10.1016/S0264-410X(02)00449-8.
10. Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5-6):557-562. DOI:10.1016/j.vaccine.2003.09.008.
11. Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, et al. Hypotonichyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5-6):563-8. DOI:10.16/j.vaccine2003.09.009.
12. Bonhoeffer J, Heininger U, Kohl K, Chen RT, Duclos P, Heijbel H et al. Standardized case definitions of adverse events following immunization (AEFI) [editorial]. Vaccine. 2004;22(5-6):547-50. DOI:10.1016/S0264-410X(03)00511-5.
13. Brito GS. Eventos adversos e segurança de vacinas. In: Farhat CK, Carvalho ES, Weckx LY, Carvalho LHF, Succi RCM. Imunizações: fundamentos e práticas. São Paulo: Atheneu; 2000. p.43-65.
14. Camacho LAB, Aguiar SG, Freire MS, Leal MLF, Nascimento JP, Iguchi T, et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica. 2005;39(3):413-20. DOI:10.1590/S0034-89102005000300012.
15. Canada. Public Health Agency. Canadian National Report on Immunization, 1996. Canada Commun Dis Rep. 1997;23(S4):1-2.
16. Centers for Disease Control and Prevention. Ten great public health achievements - United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48(12):241-3.
17. Centers for Disease Control and Prevention. Update: cardiac and other adverse events following civilian smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(27):639-42.
18. Chen RT, Harber P. Safety profiles and similarity index: new tools for assessing vaccine safety? Pharmacoepidemiol Drug Saf. 1995;4 (Suppl):S43.
19. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev. 1996;18(2):99-117.
20. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow EW, Thompson RS et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99(6):765-73. DOI:10.1542/peds.99.6.765.
21. Chen RT, DeStefano F. Vaccine adverse event: causal or coincidental? Lancet. 1998;351(9103):611-2. DOI:10.1016/S0140-6736(05)78423-3.
22. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine. 1999;17 (Suppl 3):S41-46. DOI:10.1016/S0264-410X(99)00292-3. DOI:10.1016/S0264-410X(99)00292-3.
23. Chen RT. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and casecontrol studies. Vaccine. 2004;22(15-16):2047-53. DOI:10.1016/j.vaccine.2004.01.023.
24. Chen RT, Davis RL, Sheedy KM. Safety of immunizations. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4.ed. Philadelphia: Elsevier; 2004. p.1557-81.
25. Classen DC, Classen JB. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect Dis Clin Pract. 1997;6:449-54. DOI:10.1097/00019048-199706070-00007.
26. Clemens JD, Nacify A, Rao MR, Koo H. Longer term evaluation of vaccine protection: methodological issues for Phase III and Phase IV studies. In: Levine MM, Kaper JB, Rapuoli R, Liu MA, Good MF, editors. New generation vaccines. 3. ed. New York: Marcel Dekker; 2004. p.29-48.
27. Clements CJ, Larsen G, Jodar L. Technologies that make administration of vaccines safer. Vaccine. 2004;22(15-16);2054-8. DOI:10.1016/j.vaccine.2004.01.008.
28. Collet JP, MacDonald N, Cashman N, Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Vaccination benefits, risks and safety: the need for a complete picture. Bull World Health Organ. 2000;78(2):178-85.
29. Cunha SS, Rodrigues LC, Barreto LM, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine. 2002;20(7-8):1106-12. DOI:10.1016/S0264-410X(01)00438-8.
30. Cunha SC, Dourado I. MMR mass vaccination campaigns, vaccine-related adverse events, and the limits of the decision making process, in Brazil. Health Policy. 2004;67:323-8. DOI:10.1016/j.healthpol.2003.07.008.
31. Delamonica E, Minujin A, Gulaid J. Monitoring equity in immunization coverage. Bull World Health Organ. 2005;83(5):384-91. DOI:10.1590/S0042-96862005000500016.
32. Daley MF, Barrow J, Pearson K, Crane LA, Gao D, Stevenson JM, et al. Identification and recall of children with chronic medical conditions for influenza vaccination. Pediatrics. 2004;113(1 Pt 1):e26-33. DOI:10.1542/peds.113.1.e26.
33. Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16(3):336-41.
34. Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for Immunization programs. Am J Epidemiol. 2000;151(5):524-30.
35. Duclos P, Delo A, Aguado T, Bilous J, Birmingham M, Kieny MP, et al. Immunization safety priority project at the World Health Organization. Semin Pediatr Infect Dis. 2003;14(3):233-9. DOI:10.1016/S1045-1870(03)00038-4.
36. Duclos P. A global perspective on vaccine safety. Vaccine. 2004;22(15-16): 2059-63. DOI:10.1016/j. vaccine.2004.01.010.
37. Ellenberg SS, Braun MM. Monitoring the safety of vaccines: assessing the risks. Drug Safety. 2002;25(3):145-52. DOI:10.2165/00002018-200225030-00001.
38. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep. 1997;112(1):10-20.
39. Evans D, Cauchemez S, Hayden FG. "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis. 2009;200(3):321-8. DOI:10.1086/603560.
40. Expanded programme on immunization. Safety of high-titre measles vaccines. Wkly Epidemiol Rec. 1992;67(48):357-61.
41. Falleiros-Carvalho LH, Weckx LY. Uso universal da vacina inativada contra poliomielite. J Pediatr (Rio J). 2006;82(3 Suppl):S75-82. DOI:10.1590/S0021-75572006000400009.
42. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Caner P, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567-9. DOI:10.1016/S0140-6736(95)90471-7.
43. Fine PEM, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136 (2):121-35.
44. Fishbein DB, Willis BC, Cassidy WM, Marioneaux D, Bachino C, Waddington T, et al. Determining indications for adult vaccination: patient self-assessment, medical record or both? Vaccine. 2006;24(6):803-18. DOI:10.1016/j.vaccine.2005.07.093.
45. Freitas FRM, Sato HK, Aranda CMSS, Arantes BAF, Pacheco MA, Waldman EA. Eventos adversos pós-vacina contra a difteria, coqueluche e tétano e fatores associados à sua gravidade. Rev Saude Publica. 2007;41(6):1032-41. DOI:10.1590/S0034-89102007000600019.
46. Galindo Santana BM, Galindo Sardiña MA, Pérez Rodrigues A. Sistema de vigilancia de eventos adversos consecutivos a la vacunación en la República de Cuba. Rev Cubana Med Trop. 1999;51(3):194-200.
47. Galler R, Pugachev KV, Santos CLS, Ocran SW, Jabor AV, Rodrigues SG, et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001;290(2):309-19. DOI:10.1006/viro.2001.1168.
48. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998;351(9099):356-61. DOI:10.1016/S0140-6736(97)04334-1.
49. Gary HE Jr., Smith B, Jenks J, Ruiz J, Sessions W, J. Vinje J, et al. Failure to detect infection by oral polio vaccine virus following natural exposure among inactivated polio vaccine recipients. Epidemiol Infect. 2008;136(2):180-3. DOI:10.1017/S0950268807008321.
50. Geier DA, King PG, Sykes LK, Mark R. Geier MR. RotaTeq vaccine adverse events and policy considerations. Med Sci Monit. 2008;14(3):PH9-16.
51. Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009:48(4):456-61.
52. German RR, Lee LM, Horan JM, Milstein RL, Pertowski CA, Waller MN. Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group. MMWR Recom Rep. 2001;50(RR-13):1-35.
53. Harden VA. National Institutes of Health celebrating 100 year of medical progress. In: Bernstein E, editor. Medical and health annual. Chicago: Encyclopaedia Britannica;1988. p.158-76.
54. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146(10):789-803.
55. Heijbel H. Improving vaccine safety through the uses of immunisation registers and bar code labelled vacines. Vaccine. 2002;20 (Suppl 1):S75-7. DOI:10.1016/S0264-410X(01)00296-1.
56. Heininger U. The success of immunization- shovelling its own grave? Vaccine. 2004;22(15-16):2071-2. DOI:10.1016/j.vaccine.2004.01.018.
57. Insel RA. Potencial alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci. 1995;754:35-47. DOI:10.1111;j.1749-6632.1995.tb44436.x.
58. Iskander JK, Miller ER, Pless RP, Chen RT. Vaccine safety post-marketing surveillance: the Vaccine Adverse Event Reporting System. Atlanta: US Department of Health and Human Services, CDC, National Immunization Program; 2006.
59. Jansen VAA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science. 2003;301(5634):804. DOI:10.1126/science.1086726.
60. Jefferson T. Vaccination and its adverse effects: real or perceived. Society should think about means of linking exposure to potential long-term effect. BMJ. 1998;317(7152):159-60.
61. Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and Pasteur-Mérieux serums and vaccines. Pediatr Infec Dis J. 1996;15(1):44-8. DOI:10.1097/00006454-199601000-00010.
62. Kaper JB, Rappuoli R. An overview of biotechnology in vaccine development. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, editors. New generation vaccines. 3.ed. New York: Marcel Dekker; 2004. p.11-17.
63. Kelso JM. The gelatin story. J Allergy Clin Immunol. 1999;103(2 Pt 1):200-2. DOI:10.1016/S0091-6749(99)70490-2.
64. Kemp T, Pearce N, Fitzharris P, Crane J, Fergusson D, St George I, et al. Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology. 1997;8(6):678-80. DOI:10.1097/00001648-199710000-00011.
65. Kohl KS, Jan Bonhoeffer J, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Safe. 2003;12(4):335-40. DOI:10.1002/pds.851.
66. Kohl KS, Magnus M, Ball R, Halsey N, Shadomy S, Farley TA. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. Vaccine. 2008;26(50):6349-60. DOI:10.1016/j.vaccine.2008.09.002.
67. Lane JM, Millar JD. Routine childhood vaccination against smallpox reconsidered. N Engl J Med. 1969;281(22):1220-4. DOI:10.1056/NEJM196911272812205.
68. Lankinen KS, Pastila S, Kilpi T, Nohynek H, Mäkelä PH, Olin P. Vaccinovigilance in Europe: need for timeliness, standardization and resources. Bull World Health Organ. 2004;82(110):828-35. DOI:/S0042-96862004001100007.
69. Laporte JR, Tognoni G. Principios de epidemiología del medicamento. 2.ed. Barcelona: Masson-Salvat; 1993. Estudios de utilización de medicamentos y de farmacovigilância; p.1-24.
70. Lawrence G, Menzies R, Burgess M, McIntyre P, Word N, Boyd I, et al. Surveillance of adverse events following immunization: Australia, 2000-2002. Commun Dis Intell. 2003;27(3):307-23.
71. Lenz W. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:45. DOI:10.1016/S0140-6736(62)92665-X.
72. Levine MM. Vaccines and vaccination in the historical perspective. In: Levine MM, Woodrow GC, editors. New generation vaccines. New York: Marcel Dekker; 1990. p.3-17.
73. Luhm KR, Waldman EA. Sistemas informatizados de registro de imunização: uma revisão com enfoque na saúde infantil. Epidemiol Serv Saude. 2009;18(1):65-78.
74. Mansoor O, Pillans PI. Vaccine adverse events reported in New Zeland 1900-5. N Z Med J. 1997;110(1048):270-2.
75. Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004;22(5-6):551-6. DOI:10.1016/j.vaccine.2003.09.007.
76. Martins RM, Camacho LAB, Lemos MCF, Noronha TG, Carvalho MHC, Greffe N, et al. Incidência de episódios hipotônicos-hiporresponsivos associados à vacina combinada DTP/Hib usada no Program a Nacional de Imunizações. J Pediatr (Rio J). 2007;83(6):523-8. DOI:10.1590/S0021-75572007000800008.
77. Meyboom RHB, Hekster YA, Egberts ACG, Gribnau FWJ, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety. 1997;17(6):374-89. DOI:10.2165/00002018-199717060-00004.
78. Moher D, Schultz KF, Altman DG; CONSORT Group. The CONSORT statement: revised recommendation for improving the quality of reports of parallel group randomised trials. Ann Intern Medicine. 2001;34(8):657-62.
79. Monteiro SAMG, Takano OK, Waldman EA. Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting. Vaccine. 2010;28(18):3127-33. DOI:10.1016/j.vaccine.2010.02.059.
80. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine. 2001;19(32):4627-34. DOI:10.1016/S0264-410X(01)00237-7.
81. Olmsted SS, Grabenstein JD, Jain AK, Comerford W, Giambo P, Johnson P, et al. Use of an electronic monitoring system for self-reporting smallpox vaccine reactions. Biosecur Bioterror. 2005;3(13):198-206. DOI:10.1089/bsp.2005.3.198.
82. Olmsted SS, Grabenstein JD, Jain AK, Lurie N. Patient experience with, and use of, an electronic monitoring system to assess vaccination responses. Health Expect. 2006;9(12):110-7. DOI:10.1111/j.1369-7625.2006.00378.x.
83. Omer SB, Salmon DA, Orenstein WA, De Hart P, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360(19):1981-8. DOI:10.1056/NEJMsa0806477.
84. Pless RP, Bentsi-Enchill AD, Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic Issues. J Infect Dis. 2003;187 (Suppl 1):S291-8. DOI:10.1086/368049.
85. Postila V, Kilpi T. Use of surveillance data in the evaluation of safety of vaccines. Vaccine. 2004;22(15-16):2076-9. DOI:10.1016/j.vaccine.2004.01.020.
86. Prevots DR, Parise MS, Segatto TCV, Siqueira MM, Santos ED, Ganter B, et al. Interruption of measles transmission in Brazil, 2000-2001. J Infect Dis. 2003;187 (Suppl 1):S111-20. DOI:10.1086/368030.
87. Puffer R, Serrano C. Características de la mortalidad en la niñez. Washington, DC; Pan-American Health Organization; 1973. (OPS Publicación Científica, 262).
88. Rothstein E, Kohl KS, Ball L, Halperin SA, Halsey N, Hammer SJ, et al. Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5-6):575-85. DOI:10.1016/j.vaccine.2003.09.005.
89. Sangrujee N, Cáceres VM, Cochi SL. Cost analysis of post-polio certification immunizations policies. Bull World Health Organ. 2004;82(1):9-15. DOI:10.1590/S0042-96862004000100005.
90. Schmitt HJ. Factors influencing vaccine uptake in Germany. Vaccine. 2002;20 (Suppl 1):S2-4. DOI:10.1016/S0264-410X(01)00304-8.
91. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegle DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccinations in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110(2):105-23.
92. Silva LJ. Vacinação, segurança de imunobiológicos e direitos do cidadão [editorial]. Rev Saude Publica. 1996;30(4):297-8. DOI:10.1590/S0034-89101996000400001.
93. Silveira CM, Kmetzsch CI, Mohrtdieck R, Sperb AF, Prevots DRl. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumpsrubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol. 2002;31(5):978-82. DOI:10.1093/ije/31.5.978.
94. Smeeth L, Rodrigues LC, Hall AJ, Fombonne E, Smith PG. Evaluation of adverse effects of vaccines: the case-control approach. Vaccine. 2002;20(19-20):2611-7. DOI:10.1016/S0264-410X(02)00147-0.
95. Smith A, Yarwood J, Salisbury DM. Tracking mothers' attitudes to MMR immunisation 1996-2006. Vaccine. 2007;25(20):3996-4002. DOI:10.1016/j.vaccine.2007.02.071.
96. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine. 1999;17(22):2908-17. DOI:10.1016/S0264-410X(99)00132-2.
97. Sokhey J. Adverse events following immunization: 1990. Indian Pediatr. 1991;28(6):593-607.
98. Stetler HC, Mullen JR, Brennan JP, Livengood JR, Orenstein WA, Hinman AR. Monitoring system for adverse events following immunization. 1987;5(3):169-74. DOI:10.1016/0264-410X(87)90094-6.
99. Thacker SB, Berkelman RL. Surveillance of medical technologies. J Public Health Policy. 1986;7(3):363-77. DOI:10.2307/3342463.
100. Tacket CO, Kotloff KL, Rennels MB. Initial clinical evaluation of new vaccine candidates: investigators' perspective of Phase I and II clinical trials of safety, immunogenicity, and preliminary efficacy. In: Levine MM, Kaper JB, Rapuoli R, Liu MA, Good MF, editors. New generation vaccines. 3.ed. New York; Marcel Dekker; 2004. p.19-28.
101. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun M, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23(4):287-94.
102. Vasconcelos PFC, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VLRS, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91-7. DOI:10.1016/S0140-6736(01)05326-0.
103. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. RETRACTED: Ileallymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637-41. DOI:10.1016/S0140-6736(97)11096-0.
104. Waldman EA, Silva LJ, Monteiro CA. Trajetória das doenças infecciosas: da eliminação da poliomielite à reintrodução da cólera. In: Monteiro CA. Velhos e novos males da saúde no Brasil: a evolução do país e de suas doenças. 2a. ed. São Paulo: Hucitec, Nupens/USP; 2000. p.195-244.
105. Waldman EA. Usos da vigilância e da monitorização em saúde pública. Inf Epidemiol SUS. 1998;7(3):7-26.
106. Waldman EA. Elevadas coberturas, equidade e segurança: desafios do Programa Nacional de Imunizações. Rev Bras Epidemiol. 2008;11 (Suppl 1):129-32.
107. Ward BJ. Vaccine adverse events in the new millenium: is there reason for concern? Bull World Health Organ. 2000;78(2):205-15.
108. Weijer C, Lanata CF. Ethical consideration in the conduct of vaccine trials in developing countries. In: Levine MM, Kaper JB, Rapuoli R, Liu MA, Good MF, editors. New generation vaccines. 3.ed. New York: Marcel Dekker; 2004. p.49-55.
109. World Health Organization. Immunization safety surveillance: guideline for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila; 1999.
110. World Health Organization. Supplementary information on vaccine safety. Part 2: Background rates of adverse events following immunization. Geneva; 2002.
111. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva; 2002. Pharmacovigilance in drug regulation; Chapter 4.
112. World Health Organization. Safety of mass immunization campaigns. Geneva: WHO Department of Vaccines and Biologicals; 2002.
113. Zanoni G, Nguyen TMD, Valsecchi M, Gallo G, Tridente G. Prevention and monitoring of adverse events following immunization: the "Green Channel" of the Veneto region in Italy. Vaccine. 2003;22(2):194-201. DOI:10.1016/S0264-410X(03)00566-8.
114. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS), USA, 1991-2001. MMWR Surveill Summ. 2003;52(1):1-24.